tbuckley/cabot-search huggingface dataset:
ARTIFICIAL COLORATION OF CITRUS FRUITS
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Special Article.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Second International Congress of the T. and L. de Beaumont Bonelli Foundation for Cancer Research
Journal: JNCI Journal of the National Cancer Institute (1982)

Second International Congress of the T. and L. de Beaumont Bonelli Foundation for Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 68, Issue 4, April 1982, Page 695, https://doi.org/10.1093/jnci/68.4.695-f Published: 01 April 1982
Current Medical Literature
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction to: Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension
Authors: Na Zhu, Michael W. Pauciulo, Carrie L. Welch, Katie A. Lutz, Anna W. Coleman, Claudia Gonzaga-Jauregui, Jiayao Wang, Joseph M. Grimes, Lisa J. Martin, Hua He, Yufeng Shen, Wendy K. Chung, William C. Nichols
Journal: Genome Medicine (2022)
BERLIN
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Elevated Serum Aminotransferases
Authors: Kristel K. Leung, Gideon M. Hirschfield
Journal: JAMA (2022)

A previously healthy 50-year-old woman presented with 3 weeks of fatigue, nausea, dark urine, pruritus, and scleral icterus. She had a serum aminotransferase value of 1198 U/L, antinuclear antibody titer of 1:160, and IgG concentration of 1940 mg/dL. What would you do next?
Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells
Authors: Tracy J. Berg, Alexander Pietras
Journal: Seminars in Cancer Biology (2022)

Cancer cells reside amongst a complex milieu of stromal cells and structural features known as the tumor microenvironment. Often cancer cells divert and co-opt functions of stromal cells of the microenvironment to support tumor progression and treatment resistance. During therapy targeting cancer cells, the stromal cells of the microenvironment receive therapy to the same extent as cancer cells. Stromal cells therefore activate a variety of responses to the damage induced by these therapies, and some of those responses may support tumor progression and resistance. We review here the response of stromal cells to cancer therapy with a focus on radiotherapy in glioblastoma. We highlight the response of endothelial cells and the vasculature, macrophages and microglia, and astrocytes, as well as describing resulting changes in the extracellular matrix. We emphasize the complex interplay of these cellular factors in their dynamic responses. Finally, we discuss their resulting support of cancer cells in tumor progression and therapy resistance. Understanding the stromal cell response to therapy provides insight into complementary therapeutic targets to enhance tumor response to existing treatment options.
Renal Transplantation
Authors: Ralph A. Straffon
Journal: JAMA (1968)

In the four years since the first edition, a wealth of information has accumulated in the basic sciences related to transplantation. As of December 1967, renal transplantation has been performed more than 1,200 times, and the results now being achieved indicate that this surgical procedure should be considered in the treatment of terminal renal failure. This second edition is a remarkably up-to-date review of the entire field of renal transplantation, with particular emphasis on experimental studies in animals. The first section of the book deals with the mechanisms of homograft rejection and how it may be prevented. This includes attempts (1) to render the renal graft nonantigenic, (2) to prevent the antigenic material from reaching the lymphoid system, (3) to prevent the recognition of the antigenic material by the recipient, (4) to prevent the central mechanism from reacting against the antigenic material, and (5) to prevent lymphoid cells from reaching
Errors in Methods
Journal: JAMA Network Open (2022)

Tsung-Lin Tsai, PhD; Shu-Li Wang, PhD; Chia-Jung Hsieh, PhD; Hui-Ju Wen, PhD; Chin-Chi Kuo, MD, PhD; Huei-Ju Liu, MS; Chien-Wen Sun, MS; Mei-Lien Chen, PhD; Ming-Tsang Wu, MD, PhD; TMICS Study Group; Ying- Chih Tseng; Chaw-Liang Chang; Tsung-Ho Ying ; Pen-Hua Su ; Kuei-Cheng Hsu ; Hsiao-Neng Chen ; Jian-Wun Cian ; Wei-Te Lei ; Sheng-Po Kao; Yu-Chi Wei ; Yu-Hsun Chang ; Fu-Chen Kuo ; Chien-Yi Wu
Clinical Nephrology
Authors: Leonard B. Berman
Journal: JAMA (1972)

Nephrology books, like sweaters, come in three sizes, small, medium, and large. Dr. Papper's book is medium. Its 539 well-printed pages represent a reasonable summary of current concepts in nephrology. The illustrations are quite good, particularly the drawings by Obaya. Each chapter is provided with a reading list which is brief and helpful. We can share the author's amusement with the "all purpose urinalysis" which is the familiar laboratory report of a little bit of protein and a few white cells in everybody's urine. Renal services have long ago learned the necessity of looking at their patients' urines themselves. The list of preventable and treatable renal diseases is a welcome reminder of how much we can do for our patients if we break through the aura of defeatism that surrounds renal failure. Dr. Papper's editorial judgment is good—he deals with controversy fairly and briefly. The book has its problems. It
HOLLAND
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized placebo‐controlled trial of losartan for pediatric NAFLD
Authors: Miriam B. Vos, Mark L. Van Natta, Niviann M. Blondet, Srinivasan Dasarathy, Mark Fishbein, Paula Hertel, Ajay K. Jain, Saul J. Karpen, Joel E. Lavine, Saeed Mohammad, Laura A. Miriel, Jean P. Molleston, Marialena Mouzaki, Arun Sanyal, Emily P. Sharkey, Jeffrey B. Schwimmer, James Tonascia, Laura A. Wilson, Stavra A. Xanthakos
Journal: Hepatology (2022)

Abstract Background and Aims To date, no pharmacotherapy exists for pediatric NAFLD. Losartan, an angiotensin II receptor blocker, has been proposed as a treatment due to its antifibrotic effects. Approach and Results The Nonalcoholic Steatohepatitis Clinical Research Network conducted a multicenter, double‐masked, placebo‐controlled, randomized clinical trial in children with histologically confirmed NAFLD at 10 sites (September 2018 to April 2020). Inclusion criteria were age 8–17 years, histologic NAFLD activity score ≥ 3, and serum alanine aminotransferase (ALT) ≥ 50 U/l. Children received 100 mg of losartan or placebo orally once daily for 24 weeks. The primary outcome was change in ALT levels from baseline to 24 weeks, and the preset sample size was n = 110. Treatment effects were assessed using linear regression of change in treatment group adjusted for baseline value. Eighty‐three participants (81% male, 80% Hispanic) were randomized to losartan ( n = 43) or placebo ( n = 40). During an enrollment pause, necessitated by the 2019 coronavirus pandemic, an unplanned interim analysis showed low probability (7%) of significant group difference. The Data and Safety Monitoring Board recommended early study termination. Baseline characteristics were similar between groups. The 24‐week change in ALT did not differ significantly between losartan versus placebo groups (adjusted mean difference: 1.1 U/l; 95% CI = −30.6, 32.7; p = 0.95), although alkaline phosphatase decreased significantly in the losartan group (adjusted mean difference: −23.4 U/l; 95% CI = −41.5, −5.3; p = 0.01). Systolic blood pressure decreased in the losartan group but increased in placebo (adjusted mean difference: −7.5 mm Hg; 95% CI = −12.2, −2.8; p = 0.002). Compliance by pill counts and numbers and types of adverse events did not differ by group. Conclusions Losartan did not significantly reduce ALT in children with NAFLD when compared with placebo.
Standards for monitoring during anesthesia at Harvard
Authors: Maxwell Weingarten
Journal: JAMA (1987)

<h3>To the Editor.—</h3> I would like to applaud Eichhorn et al<sup>1</sup>for their article on standards for patient monitoring during anesthesia. This article should provide a powerful impetus for the adoption of mandatory standards, as is currently being encouraged by the American Society of Anesthesiologists and the Food and Drug Administration through their patient-safety videotapes. In particular, the author's recommendation that ventilation or circulation be continuously monitored will certainly aid in the early detection of catastrophic events. However, the selection of only one parameter "or the equivalent" may be inadequate, and it is becoming increasingly evident that if outcome is to be changed, the adequacy of both ventilation and oxygenation must be monitored. For example, "palpation or observation of the reservoir breathing bag" will not accurately differentiate hypoventilation or hyperventilation, an abnormal respiratory pattern, or an incorrect gas mixture. "Auscultation of breath sounds" has repeatedly been found, as previously
FAMILY DISEASES.
Authors: WHARTON SINKLER
Journal: JAMA (1900)

The term "family diseases" includes a wide field in medicine as to generations and yet is perhaps more limited in number of actual cases existing than the monograph and text-book articles would lead us to believe at casual observation of these very interesting phenomena. The object of this contribution to the familial affections is to present all the cases that could be found within the direct and indirect observation of the authors. For it is only by such personal considerations that the true bearing of so difficult a problem can be elucidated in proper relation to the individual practitioner. We can perhaps best divide the subject, broadly, into the classes: 1. Hereditary maladies. 2. Family tendency to a certain disease in special generations without hereditary taint. Then subdivisions may be rightly made into the more general and hereditary, or not, affections, involving for example the cardiovascular or pulmonary systems or
Association of Intraoperative Transesophageal Echocardiography and Clinical Outcomes After Open Cardiac Valve or Proximal Aortic Surgery
Authors: Emily J. MacKay, Bo Zhang, John G. Augoustides, Peter W. Groeneveld, Nimesh D. Desai
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Intraoperative transesophageal echocardiography (TEE) is used frequently in cardiac valve and proximal aortic surgical procedures, but there is a lack of evidence associating TEE use with improved clinical outcomes. <h3>Objective</h3> To test the association between intraoperative TEE use and clinical outcomes following cardiac valve or proximal aortic surgery. <h3>Design, Setting, and Participants</h3> This matched, retrospective cohort study used national registry data from the Society of Thoracic Surgeon (STS) Adult Cardiac Surgery Database (ACSD) to compare clinical outcomes among patients undergoing cardiac valve or proximal aortic surgery with vs without intraoperative TEE. Statistical analyses used optimal matching within propensity score calipers to conduct multiple matched comparisons including within-hospital and within-surgeon matches, a negative control outcome analysis, and sensitivity analyses. STS ACSD data encompasses more than 90% of all hospitals that perform cardiac surgery in the US. The study cohort consisted of all patients aged at least 18 years undergoing open cardiac valve repair or replacement surgery and/or proximal aortic surgery between 2011 and 2019. Statistical analysis was performed from October 2020 to April 2021. <h3>Exposures</h3> The exposure was receipt of intraoperative TEE during the cardiac valve or proximal aortic surgery. <h3>Main Outcomes and Measures</h3> The primary outcome was death within 30 days of surgery. The secondary outcomes were (1) a composite outcome of stroke or 30-day mortality and (2) a composite outcome of reoperation or 30-day mortality. <h3>Results</h3> Of the 872 936 patients undergoing valve or aortic surgery, 540 229 (61.89%) were male; 63 565 (7.28%) were Black and 742 384 (85.04%) were White; 711 326 (81.5%) received TEE and 161 610 (18.5%) did not receive TEE; the mean (SD) age was 65.61 years (13.17) years. After matching, intraoperative TEE was significantly associated with a lower 30-day mortality rate compared with no TEE: 3.81% vs 5.27% (odds ratio [OR], 0.69 [95% CI, 0.67-0.72];<i>P</i> &lt; .001), a lower incidence of stroke or 30-day mortality: 5.56% vs 7.01% (OR, 0.77 [95% CI, 0.74-0.79];<i>P</i> &lt; .001), and a lower incidence of reoperation or 30-day mortality: 7.18% vs 8.87% (OR, 0.78 [95% CI, 0.76-0.80];<i>P</i> &lt; .001). Results were similar across all matched comparisons (including within-hospital, within-surgeon matched analyses) and were robust to a negative control and sensitivity analyses. <h3>Conclusions and Relevance</h3> Among adults undergoing cardiac valve or proximal aortic surgery, intraoperative TEE use was associated with improved clinical outcomes in this cohort study. These findings support routine use of TEE in these procedures.
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Authors: Kathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, Linan Song, Eliseo Veras, Megan Wind-Rotolo, David F McDermott, F Stephen Hodi, Toni K Choueiri, Gordon J Freeman
Journal: Journal for ImmunoTherapy of Cancer (2022)

Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC) and melanoma patients, and investigated its relationship to clinical factors, biomarkers, and outcome.
Medical News
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior
Authors: Alba Rodriguez-Martinez, Iris Simon-Saez, Sonia Perales, Carmen Garrido-Navas, Alessandro Russo, Diego de Miguel-Perez, Ignacio Puche-Sanz, Clara Alaminos, Jorge Ceron, Jose A. Lorente, Maria Pilar Molina, Coral Gonzalez, Massimo Cristofanilli, Alba Ortigosa-Palomo, Pedro J. Real, Christian Rolfo, María J. Serrano
Journal: Theranostics (2022)

Background: Platelets are active players in tumorigenesis, although the exact interactive mechanisms and their direct impact on tumor cells remain largely unknown.Methods: Bidirectional transference of lipids, proteins and RNA between platelets and tumor cells and its impact on tumor cell behavior and tumor process are analyzed in this work.Phenotypic, genetic and functional modifications induced by platelets were analyzed both in tumor cell lines and in circulating tumor cells (CTCs).Results: Data from these assays showed that platelets transferred structural components to tumor cells with higher efficiency than tumor cells to platelets (p = 0.001).This biological interplay occurred by direct contact, internalization or via extracellular vesicles.As a result, tumor cells acquired platelet markers (CD61 and CD42), showed decreased EpCAM, expressed epithelial-to-mesenchymal transition markers, and increased proliferation rates.Moreover, we were able to detect CD61 in CTCs from early and advanced prostate cancer.Conclusions: Our results demonstrated, for the first time, that platelets educate tumor cells by highly efficient transference of lipids, proteins and RNA through different mechanisms.These results suggest that tumor cells and CTCs might acquire highly dynamic and aggressive phenotypes due to platelets interaction including EMT, stem-like phenotype and high proliferative rates.